title: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
authors.affiliation: Departments of Hepatology, Hôpital Beaujon, Clichy, AP-HP, France. violaine.ozenne@bjn.aphp.fr
authors.forename: Violaine
authors.initials: V
authors.lastname: Ozenne
authors.forename: Valerie
authors.initials: V
authors.lastname: Paradis
authors.forename: Simon
authors.initials: S
authors.lastname: Pernot
authors.forename: Corinne
authors.initials: C
authors.lastname: Castelnau
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Vullierme
authors.forename: Mohamed
authors.initials: M
authors.lastname: Bouattour
authors.forename: Dominique
authors.initials: D
authors.lastname: Valla
authors.forename: Olivier
authors.initials: O
authors.lastname: Farges
authors.forename: Françoise
authors.initials: F
authors.lastname: Degos
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000008:administration & dosage* / Q000009:adverse effects*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000401:mortality; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000401:mortality; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects*; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000077157:Sorafenib; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib